Starting a century ago, CSL Behring made a promise to save lives and protect the health of people. Today that same promise has never been stronger. A global leader in the biotherapeutics industry, CSL Behring is passionate about improving the quality of patients’ lives and remains committed to the global bleeding disorders community. The company manufactures and markets a range of recombinant and plasma-derived products for the treatment of Hemophilia, von Willebrand’s disease and other bleeding disorders. For more information, please visit our website.
Daiichi – Sankyo
Daiichi Sankyo and its 15,000 employees in more than 20 countries are dedicated to the creation and supply of innovative pharmaceutical products. In addition to a strong portfolio of medicines for hypertension and thrombotic disorders, the Group’s 2025 vision is to become a “Global Pharma Innovator with Competitive Advantage in Oncology”. Our European headquarters are in Munich, Germany and we have affiliates in 12 European countries. For more information visit the website.
Headquartered in Lachen, Switzerland, Octapharma is one of the largest human protein manufacturers in the world, developing and producing human proteins from human plasma and human cell lines. As a family-owned company, Octapharma believes in investing to make a difference in people’s lives and has been doing so since 1983; because it’s in our blood.
Octapharma employs more than 7,700 people worldwide to support the treatment of patients in 113 countries with products across three therapeutic areas:
• Critical care
Octapharma has seven R&D sites and six manufacturing facilities in Austria, France, Germany, Mexico and Sweden.
Sobi is an international rare disease company dedicated to providing access to innovative treatments that make a significant difference for people with rare diseases.
Sobi is an integrated biotechnology company with in-house capabilities that encompass the entire value chain, from research, to preclinical and clinical development, biologics manufacturing and supply, to patient access and distribution.
We have two business areas: Haemophilia and Specialty Care. Our research and product portfolio is primarily focused on haemophilia, inflammation, and genetic and metabolic diseases. In Haemophilia, we aim to take a leadership position in Europe, the Middle East and Africa.
Among the leaders of research-based healthcare companies, the Roche group is committed to improve the lives of patients in areas of high unmet medical needs through the development of innovative treatments and diagnostic solutions.
In pharma, Roche has 3 R&D units worldwide, also known as Genentech in the US and Chugai in Japan.
Since 2002, the Alliance between Roche and Chugai led to successful collaborations in areas such as Immunology, Oncology and most recently Haemophilia.
Shire is the global biotechnology leader serving patients with rare diseases and specialized conditions. We seek to push boundaries through discovering and delivering new possibilities for patients communities across our portfolio of therapeutic areas including Immunology, Hematology, Genetic Diseases, Internal Medicine, Ophthalmics, Oncology, and neuropsychiatry disorders.
At Spark Therapeutics, we are leveraging our unique technical and R&D expertise as we strive to bring gene therapies to patients. One of our areas of research is hemophilia A, an inherited bleeding disorder caused by mutations in the F8 gene that encodes coagulation factor VIII. Led by researchers and clinicians with long-standing commitment to the hemophilia community, we recognize the essential need to understand and gain important perspectives from patients, caregivers and leaders in the community.
Stago, created in 1945, is an IVD Company which develops and markets reagents and automated systems for the investigation of blood coagulation disorders. Stago is a leading player in Haemostasis. Headquarters, as well as R&D, manufacturing and logistics activities are located mainly in the Paris area (France). Its products are also available in more than 110 countries throughout the world through a network of 15 affiliates and 95 distributors. In 2018, Stago has more than 2,350 employees worldwide.
Stago BioCare markets Point-of-Care solutions to assist clinicians in managing critical bleeding.
Bayer is an international company with wide Life Science expertise. The Pharmaceuticals Division offers, to healthcare professionals and patients, therapeutic products for different clinical fields: cardiology, oncology, women’s health, hematology, ophthalmology and also radiology. By facilitating diagnosis and treatment, Bayer products contribute to improving the well-being and quality of life.
For more information go to: www.bayer.fr
Kedrion Biopharma is a biopharmaceutical company that collects and fractionates blood plasma to produce and distribute plasma-derived therapies for use in treating patients suffering from Hemophilia, Immunodeficiencies and other serious illnesses.
We are privileged to provide this service and do so with a profound sense of responsibility.
Founded in 1908 LEO Pharma is an independent research-based pharmaceutical company. LEO Pharma develops, manufactures and markets pharmaceutical drugs to dermatologic and thrombotic patients in more than 100 countries. LEO Pharma employs around 5,000 employees worldwide. The company is headquartered in Denmark and is wholly owned by the LEO Foundation.
LFB Group has been developing, manufacturing and marketing biological medicines, for diseases that are always serious and often rare. LFB Group is one of the leading European players in biopharmaceutical, its products are medicinal products derived from living organisms in 3 major fields of therapy: immunology, haemostasis and intensive care.
Sysmex Europe GmbH, a subsidiary of the Sysmex Corporation – the global leader for haematology diagnostics and service – is among Europe’s top specialist laboratory diagnostics companies. HYPHEN BioMed specialises in developing, manufacturing and distributing in vitro diagnostic and research reagents for exploring thrombosis and haemostasis. Together, they deliver a holistic approach to haemostasis testing.
For more information go to www.sysmex.com
Everything we do, we do at the service of patients and the healthcare community.
Werfen is a global leader in In Vitro Diagnostics (IVD) with a long term commitment to providing innovative solutions for hospitals and commercial laboratories for the improvement of patient care.
Our main business is Hemostasis, Acute Care Diagnostics, and Autoimmunity.
Every day, more than 1.5 million patient samples are tested with our IVD solutions